This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Milan L. Brandon, MD

JAMA. 1976;235(7):736-737.

Abstract
The bronchodilator efficacy and safety of metaproterenol sulfate were evaluated by double-blind crossover tests against placebo at three intervals during a 90-day treatment period in 50 asthmatic children. One group of 25 patients was continuously treated with metaproterenol syrup, and the other 25 with placebo syrup. Pulmonary function tests showed statistically significant improvements in forced expiratory volume, forced expiratory volume in one second, and peak expiratory flow rate after metaproterenol administration as compared with those measurements after treatment with placebo. Biweekly global evaluations of responses to metaproterenol administration were consistently more favorable than responses to placebo. Tachycardia and blood pressure changes after metaproterenol administration were consistent with the pharmacologic properties of beta-sympathomimetic stimulants. Side effects during metaproterenol treatment were minimal and laboratory data remained normal.

(JAMA 235:736-737, 1976)

Author Affiliations
From the Allergy Medical Group of San Diego (Calif), Inc.

Footnotes
Reprint requests to Allergy Medical Group of San Diego, Inc, 2800 Third Ave at Olive, San Diego, CA 92103.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?